FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 20 ...

Core Insights - Cytek Biosciences reported a total revenue of $45.6 million for Q2 2025, reflecting a 2% decrease compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC regions, although service revenue showed growth globally and in the U.S. [5][10] - The company launched the Cytek Aurora Evo system, which is expected to enhance the adoption of its solutions and strengthen its market position [3][10] - Cytek's total recurring revenue, which includes service and reagent revenues, grew by 16% year-over-year, accounting for 32% of the total revenue over the last 12 months [10] Financial Performance - GAAP gross profit for Q2 2025 was $23.9 million, a 6% decrease from Q2 2024, with a gross profit margin of 52% compared to 55% in the previous year [6][10] - Operating expenses increased by 2% to $34.5 million, with R&D expenses decreasing by 12% to $8.8 million, while general and administrative expenses rose by 16% to $13.5 million [7][8] - The net loss for Q2 2025 was $5.6 million, an improvement from a net loss of $10.4 million in Q2 2024 [8][10] Market Outlook - The company narrowed its 2025 revenue guidance to a range of $196 million to $205 million, indicating a potential growth of -2% to +2% compared to 2024 [12] - Cytek aims to expand its installed base globally and enhance recurring revenue through its service and reagent businesses, while focusing on innovation to redefine industry standards [4][10]